Bortezomib (Velcade)

OFFICE ADMINISTRATION

JCODE: J9041

Indications for Prior Authorization:

  • Multiple Myeloma
  • Relapsed or Refractory Mantle Cell Lymphoma*
  • Relapsed or Refractory Cutaneous or Peripheral T-cell Lymphoma*
  • Waldenstrom's Macroglobinemia**

* Patient has disease recurrence or progression on or following treatment with prior chemotherapy

** Must be given with rituximab

The drug is not covered for the following conditions:

  • Metastatic colorectal cancer
  • Advanced non-small cell lung cancer
  • Metastatic neuroendocrine carcinoma
  • Metastatic melanoma
  • Metastatic sarcoma
  • Any condition not listed in the indication section above

Dosing:

Previous untreated Multiple Myeloma

  • Cycle 1-4:  Up to 1.3 mg/m2 twice a week (IV/SubQ)
  • Cycles 5-9: Up to 1.3 mg/m2 once weekly (IV/SubQ)
  • *Each cycle is 6 weeks

Refractory or relapsed Multiple Myeloma or Mantle Cell Lymphoma

  • Up to 1.3 mg/m2 weekly (IV) for two weeks
  • Repeat every three weeks

Refractory or relapsed Cutaneous or T-cell Lymphoma

  • Up to 1.3 mg/m2 (IV) for up to four doses per 21 day cycle

Peripheral T-cell Lymphoma

  • Up to 1.3 mg/m2 (IV) for up to four doses per 21 day cycle

Waldenstrom's Macroglobinemia

  • Up to 1.3 mg/m2 (IV/SubQ)

Approval Period

Renew for one year if patient has clinical response


 

Last review date: July 20, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.